HTB

HIV prevention and transmission

DSMB stops oral tenofovir monotherapy arm of VOICE PrEP study due to lack of difference compared to placebo

Treatment is prevention: ARV treatment in HPTN-052 reduces transmission by at least 96%: single transmission in treatment arm occurred before viral suppression

Daily oral tenofovir/FTC PrEP reduces heterosexual transmission by 63% in the TDF2 study

Tenofovir/FTC vs tenofovir as daily oral PrEP: preliminary results from Partners PrEP

HPTN 052 study stopped early: significant reduction in HIV transmission from early use of HIV treatment in serodifferent partners

Preventive technologies, immune-based and gene therapies, and research towards a cure

FEM-PrEP prevention study using daily Truvada halted during enrolment: interim analysis shows similar infection rates in active and placebo arms

US CDC issue preliminary guidance for use of PrEP

Pre-exposure prophylaxis (PrEP) with tenofovir/FTC reduces sexual transmission of HIV between men at high risk: results from the iPrEx study

Male circumcision retains effectiveness at reducing risk of HIV infection: 54 month results

Results from the Caprisa 004 tenofovir microbicide trial

Quadrivalent HPV vaccine reduces genital lesions and HPV acquisition in men

Lime juice is not a microbicide: do not try at home

Immune-based therapies and preventive technologies pipeline

Summaries of other studies

HIV reinfection cases reported at CROI

Treatment reduces infections by over 90%: a theme that is here to stay

Male circumcision: new data supporting protective mechanism

A caution for male circumcision programmes: high complication rates highlighted outside a trial setting

HIV reinfection reported in 10% of couples in Zambian study

Intermittent tenofovir/FTC PrEP offers monkeys some protection

Tenofovir/FTC gel protects female monkeys from SHIV

Recently infected HIV-positive Quebec residents cause more than half of new cases

Common estimate of heterosexual HIV transmission risk sometimes far too low

Implications of transmission with undetectable HIV viral load: lower limit for HIV transmission excluded from model

Case report of sexual transmission when viral load suppressed to <50 copies/mL

HIV RNA is detectable in semen in 5% patients with undetectable blood plasma viral attending fertility clinic

Tenofovir gel as a rectal microbicide: evidence for protection and priming of T-cell responses in the SIV challenge model

Genetic protection against malaria may increase susceptibility to HIV infection in people of African decent

US CDC issue reports of false-positive oral rapid tests in New York HIV testing programme

Epidemiological studies and transmission of resistance: evidence for optimism – or issues with interpretation?

Prevention of rectal transmission of SIV in macaques using FTC with tenofovir: FTC has independent protective effect even as monotherapy

K65R frequently emerges within 1-6 weeks of tenofovir monotherapy in macaques

A genome armed against HIV

Circumcision: a surprising benefit from an unkind cut

Topical microbicides: the real front line of HIV prevention

HSV-2 suppression reduces HIV and HSV shedding

Adult male circumcision reduces transmission rates over 18 months comparable to a vaccine with 65% efficacy

Lack of keratin overlaying inner foreskin may explain lower HIV infection rates in circumcised men

Sexual transmission of HIV by acutely infected individuals has a disproportionate effect on the spread of HIV and may explain the current pandemic

Transmission of drug resistance – at 11% in Europe and 17% in the UK

HIV coinfection, reinfection and superinfection

A case of intraclade HIV-1 superinfection by wild-type virus illustrates the potential to impact disease progression

Diagnosis of acute HIV infection: it’s time to get moving!

Post navigation